Avanos Medical Inc – Lobbying Governance & Transparency

Sign up to access all our data and the evidence and analysis underlying our overall scores. Once you've created an account, we'll get in touch with further details:

Lobbying Governance

Overall Assessment	Analysis	Score
None	Avanos Medical Inc provides details of its lobbying engagements but does not disclose any governance framework to guide or oversee those activities, including climate-related lobbying. The evidence shows that "Avanos is a member of AdvaMed, a medical device industry association, which lobbies on behalf of its members" and that "In 2024, Avanos participated in federal lobbying activities in the United States to help alleviate the opioid crisis through the NOPAIN Act." It also reports that "We engaged the firms ADVI and Polsinelli to advise and represent the company on Medicare coverage and payment policy issues tied to the opioid issue before the Centers for Medicare and Medicaid Services (CMS)." However, the company does not disclose who oversees or reviews its lobbying activities, how those activities are monitored to ensure alignment with corporate policy, or any process for aligning either direct lobbying or its participation in trade associations with its business or climate objectives. We found no evidence of any governance structures, responsible individuals, or procedures to manage or assess its lobbying, and no reference to climate lobbying governance at all. View Sources	E

Overall Assessment

Analysis

Score

None

Avanos Medical Inc provides details of its lobbying engagements but does not disclose any governance framework to guide or oversee those activities, including climate-related lobbying. The evidence shows that "Avanos is a member of AdvaMed, a medical device industry association, which lobbies on behalf of its members" and that "In 2024, Avanos participated in federal lobbying activities in the United States to help alleviate the opioid crisis through the NOPAIN Act." It also reports that "We engaged the firms ADVI and Polsinelli to advise and represent the company on Medicare coverage and payment policy issues tied to the opioid issue before the Centers for Medicare and Medicaid Services (CMS)." However, the company does not disclose who oversees or reviews its lobbying activities, how those activities are monitored to ensure alignment with corporate policy, or any process for aligning either direct lobbying or its participation in trade associations with its business or climate objectives. We found no evidence of any governance structures, responsible individuals, or procedures to manage or assess its lobbying, and no reference to climate lobbying governance at all.

View Sources

Lobbying Transparency

Overall Assessment	Analysis	Score
None	The company’s disclosures describe lobbying on healthcare reimbursement matters tied to the opioid crisis and on import tariffs for medical devices, but we found no information about lobbying on climate-related policies. Because none of the named policies, mechanisms, or outcomes relate to climate or the energy transition, the disclosure does not provide any transparency on climate policy lobbying.	E